Fatty liver overview: Difference between revisions

Jump to navigation Jump to search
 
(4 intermediate revisions by 3 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Fatty liver}}
{{Fatty liver}}
{{CMG}}
{{CMG}}; {{AE}}


==Overview==
==Overview==
Fatty liver is a type of [[liver disease]], characterized by [[inflammation]] of the [[liver]] with concurrent [[fat]] accumulation in liver ("steato", meaning fat, "[[hepatitis]]", meaning inflammation of the liver).  Classically seen in alcoholics, steatohepatitis also is frequently found in people with [[diabetes]] and [[obesity]].  When not associated with excessive [[alcohol]] intake, it's referred to as [[non-alcoholic steatohepatitis]], or NASH.  Steatohepatitis of either [[etiology]] may progress to [[cirrhosis]], and NASH is now believed to be a frequent cause of unexplained cirrhosis.
Physicians do not well manage fatty liver<ref name="pmid37208593">{{cite journal| author=Shelley K, Articolo A, Luthra R, Charlton M| title=Clinical characteristics and management of patients with nonalcoholic steatohepatitis in a real-world setting: analysis of the Ipsos NASH therapy monitor database. | journal=BMC Gastroenterol | year= 2023 | volume= 23 | issue= 1 | pages= 160 | pmid=37208593 | doi=10.1186/s12876-023-02794-4 | pmc=10197394 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=37208593  }} </ref>.
==Historical Perspective==


Fatty liver is a type of [[liver disease]], characterized by [[inflammation]] of the [[liver]] with concurrent [[fat]] accumulation in liver ("steato", meaning fat, "[[hepatitis]]", meaning inflammation of the liver).  Classically seen in alcoholics, steatohepatitis also is frequently found in people with [[diabetes]] and [[obesity]].  When not associated with excessive [[alcohol]] intake, it's referred to as [[non-alcoholic steatohepatitis]], or NASH.  Steatohepatitis of either [[etiology]] may progress to [[cirrhosis]], and NASH is now believed to be a frequent cause of unexplained cirrhosis.
==Classification==


==Pathophysiology==
==Pathophysiology==
Fatty liver  is the fatty degeneration of the parenchymal cells causing a yellow discoloration of the liver.  It is a reversible condition where large [[vacuole]]s of [[triglyceride]] fat accumulate in [[hepatocyte|liver cells]] via the process of [[steatosis]].  Despite having multiple causes, fatty liver disease (FLD) can be considered a single [[disease]] that occurs worldwide in those with excessive [[alcohol]] intake and those who are obese (with or without effects of [[insulin resistance]]). The condition is also associated with other diseases that influence fat [[metabolism]].<ref name="reddy">{{cite journal |author=Reddy JK, Rao MS |title=Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation |journal=Am. J. Physiol. Fatty liver disease is one of the most deadly dieases ever to be found in someone who has and its very contasious so if someons has if i were u i wouldnt be hanging around with them well thats all from me see u next time. ËĒȲȳǖGastrointest. Liver Physiol. |volume=290 |issue=5 |pages=G852-8 |year=2006 |pmid=16603729 |doi=10.1152/ajpgi.00521.2005}}</ref. Morphologically it is difficult to distinguish alcoholic FLD from non alcoholic FLD and both show micro-[[Vesicle (biology)|vesicular]] and macrovesicular fatty changes at different stages.
Fatty liver  is the fatty degeneration of the parenchymal cells causing a yellow discoloration of the liver.  It is a reversible condition where large [[vacuole]]s of [[triglyceride]] fat accumulate in [[hepatocyte|liver cells]] via the process of [[steatosis]].  Despite having multiple causes, fatty liver disease (FLD) can be considered a single [[disease]] that occurs worldwide in those with excessive [[alcohol]] intake and those who are obese (with or without effects of [[insulin resistance]]). The condition is also associated with other diseases that influence fat [[metabolism]].<ref name="reddy">{{cite journal |author=Reddy JK, Rao MS |title=Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation |journal=Am. J. Physiol. Fatty liver disease is one of the most deadly dieases ever to be found in someone who has and its very contasious so if someons has if i were u i wouldnt be hanging around with them well thats all from me see u next time. ËĒȲȳǖGastrointest. Liver Physiol. |volume=290 |issue=5 |pages=G852-8 |year=2006 |pmid=16603729 |doi=10.1152/ajpgi.00521.2005}}</ref> Morphologically it is difficult to distinguish alcoholic FLD from non alcoholic FLD and both show micro-[[Vesicle (biology)|vesicular]] and macrovesicular fatty changes at different stages.
 
==Causes==
 
==Differentiating Fatty liver from Other Diseases==


==Epidemiology and Demographics==
==Epidemiology and Demographics==
Fatty liver disease is prevalent among 10%- 24% of general population in various countries<ref name="angulo"/>. However among obese individuals the condition is observed in  up to 75% of people, 35% of whom, despite no evidence of excessive alcohol consumption, will lead to [[Non-alcoholic fatty liver disease|non alcoholic FLD]]<ref>{{cite journal |author=Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, Omatsu T, Nakajima T, Sarui H, Shimazaki M, Kato T, Okuda J, Ida K |title=The metabolic syndrome as a predictor of nonalcoholic fatty liver disease |journal=Ann. Intern. Med. |volume=143 |issue=10 |pages=722-8 |year=2005 |pmid=16287793 |doi=}}</ref>. It is the commonest cause of abnormal [[liver function test]] in the US<ref name="angulo">{{cite journal |author=Angulo P |title=Nonalcoholic fatty liver disease |journal=N. Engl. J. Med. |volume=346 |issue=16 |pages=1221-31 |year=2002 |pmid=11961152 |doi=10.1056/NEJMra011775}}</ref>. African Americans and Mexican Americans have higher frequencies of unexplained serum [[Transaminase|aminotransferase]] elevations than those reported in whites but prevalence of FLD among different racial groups is not known.
Fatty liver disease is prevalent among 10%- 24% of general population in various countries.<ref name="angulo"/> However among obese individuals the condition is observed in  up to 75% of people, 35% of whom, despite no evidence of excessive alcohol consumption, will lead to [[Non-alcoholic fatty liver disease|non alcoholic FLD]].<ref>{{cite journal |author=Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, Omatsu T, Nakajima T, Sarui H, Shimazaki M, Kato T, Okuda J, Ida K |title=The metabolic syndrome as a predictor of nonalcoholic fatty liver disease |journal=Ann. Intern. Med. |volume=143 |issue=10 |pages=722-8 |year=2005 |pmid=16287793 |doi=}}</ref> It is the most common cause of abnormal [[liver function test]] in the US.<ref name="angulo">{{cite journal |author=Angulo P |title=Nonalcoholic fatty liver disease |journal=N. Engl. J. Med. |volume=346 |issue=16 |pages=1221-31 |year=2002 |pmid=11961152 |doi=10.1056/NEJMra011775}}</ref> African Americans and Mexican Americans have higher frequencies of unexplained serum [[Transaminase|aminotransferase]] elevations than those reported in whites but prevalence of FLD among different racial groups is not known.
 
==Risk Factors==
 
==Screening==
 
==Natural History, Complications, and Prognosis==
===Natural History===
 
===Complications===
 
===Prognosis===
 
==Diagnosis==
==Diagnosis==
===History and Symptoms===
===Physical Examination===
===Laboratory Findings===
===Laboratory Findings===
Most individuals are asymptomatic and are usually discovered incidentally because of abnormal liver function tests or hepatomegaly noted in unrelated medical condition. Elevated liver biochemistry is found in 50% of patients with simple steatosis.<ref>{{cite book | last = Sleisenger | first = Marvin | title = Sleisenger and Fordtran's Gastrointestinal and Liver Disease | publisher = W.B. Saunders Company | location = Philadelphia | year = 2006 | isbn = 1416002456 }}</ref> The serum [[Alanine transaminase|ALT]] level usually is greater than the [[AST]] level in non-alcoholic variant and the opposite in alcoholic FLD.
Most individuals are asymptomatic and are usually discovered incidentally because of abnormal liver function tests or hepatomegaly noted in unrelated medical condition. Elevated liver biochemistry is found in 50% of patients with simple steatosis.<ref>{{cite book | last = Sleisenger | first = Marvin | title = Sleisenger and Fordtran's Gastrointestinal and Liver Disease | publisher = W.B. Saunders Company | location = Philadelphia | year = 2006 | isbn = 1416002456 }}</ref> The serum [[Alanine transaminase|ALT]] level usually is greater than the [[AST]] level in non-alcoholic variant and the opposite in alcoholic FLD.
===Imaging Findings===
===Other Diagnostic Studies===


==Treatment==
==Treatment==
Line 20: Line 49:
The treatment of fatty liver depends on what is causing it, and generally, treating the underlying cause will reverse the process of steatosis if implemented at early stage. Recent studies suggest that [[diet (nutrition)|diet]], [[exercise]], and especially [[anti-diabetic drug|antiglycemic drug]]s may alter the course of the disease. A [[randomized controlled trial]] found that [[pioglitazone]] led to metabolic and histologic improvement in subjects with  nonalcoholic steatohepatitis.<ref name="pmid17135584">{{cite journal |author=Belfort R, Harrison SA, Brown K, ''et al'' |title=A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis |journal=N. Engl. J. Med. |volume=355 |issue=22 |pages=2297–307 |year=2006 |pmid=17135584 |doi=10.1056/NEJMoa060326}}</ref>
The treatment of fatty liver depends on what is causing it, and generally, treating the underlying cause will reverse the process of steatosis if implemented at early stage. Recent studies suggest that [[diet (nutrition)|diet]], [[exercise]], and especially [[anti-diabetic drug|antiglycemic drug]]s may alter the course of the disease. A [[randomized controlled trial]] found that [[pioglitazone]] led to metabolic and histologic improvement in subjects with  nonalcoholic steatohepatitis.<ref name="pmid17135584">{{cite journal |author=Belfort R, Harrison SA, Brown K, ''et al'' |title=A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis |journal=N. Engl. J. Med. |volume=355 |issue=22 |pages=2297–307 |year=2006 |pmid=17135584 |doi=10.1056/NEJMoa060326}}</ref>


===Prevention===
===Surgery===
 
===Primary Prevention===
Avoidance of [[alcohol abuse]], maintenance of health diet and weight helps in preventing fatty liver.
Avoidance of [[alcohol abuse]], maintenance of health diet and weight helps in preventing fatty liver.
===Secondary Prevention===


==References==
==References==
{{Reflist|2}}
{{Reflist|2}}


[[Category:Hepatology]]
[[Category:Hepatology]]
[[Category:Medical conditions related to obesity]]
[[Category:Gastroenterology]]
[[Category:Gastroenterology]]
[[Category:Disease]]
[[Category:Disease]]
{{WS}}
{{WH}}

Latest revision as of 05:14, 2 June 2023

Fatty Liver Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Fatty Liver from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Fatty liver overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Fatty liver overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Fatty liver overview

CDC on Fatty liver overview

Fatty liver overview in the news

Blogs on Fatty liver overview

Directions to Hospitals Treating Fatty liver

Risk calculators and risk factors for Fatty liver overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

Fatty liver is a type of liver disease, characterized by inflammation of the liver with concurrent fat accumulation in liver ("steato", meaning fat, "hepatitis", meaning inflammation of the liver). Classically seen in alcoholics, steatohepatitis also is frequently found in people with diabetes and obesity. When not associated with excessive alcohol intake, it's referred to as non-alcoholic steatohepatitis, or NASH. Steatohepatitis of either etiology may progress to cirrhosis, and NASH is now believed to be a frequent cause of unexplained cirrhosis.

Physicians do not well manage fatty liver[1].

Historical Perspective

Classification

Pathophysiology

Fatty liver is the fatty degeneration of the parenchymal cells causing a yellow discoloration of the liver. It is a reversible condition where large vacuoles of triglyceride fat accumulate in liver cells via the process of steatosis. Despite having multiple causes, fatty liver disease (FLD) can be considered a single disease that occurs worldwide in those with excessive alcohol intake and those who are obese (with or without effects of insulin resistance). The condition is also associated with other diseases that influence fat metabolism.[2] Morphologically it is difficult to distinguish alcoholic FLD from non alcoholic FLD and both show micro-vesicular and macrovesicular fatty changes at different stages.

Causes

Differentiating Fatty liver from Other Diseases

Epidemiology and Demographics

Fatty liver disease is prevalent among 10%- 24% of general population in various countries.[3] However among obese individuals the condition is observed in up to 75% of people, 35% of whom, despite no evidence of excessive alcohol consumption, will lead to non alcoholic FLD.[4] It is the most common cause of abnormal liver function test in the US.[3] African Americans and Mexican Americans have higher frequencies of unexplained serum aminotransferase elevations than those reported in whites but prevalence of FLD among different racial groups is not known.

Risk Factors

Screening

Natural History, Complications, and Prognosis

Natural History

Complications

Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Most individuals are asymptomatic and are usually discovered incidentally because of abnormal liver function tests or hepatomegaly noted in unrelated medical condition. Elevated liver biochemistry is found in 50% of patients with simple steatosis.[5] The serum ALT level usually is greater than the AST level in non-alcoholic variant and the opposite in alcoholic FLD.

Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

The treatment of fatty liver depends on what is causing it, and generally, treating the underlying cause will reverse the process of steatosis if implemented at early stage. Recent studies suggest that diet, exercise, and especially antiglycemic drugs may alter the course of the disease. A randomized controlled trial found that pioglitazone led to metabolic and histologic improvement in subjects with nonalcoholic steatohepatitis.[6]

Surgery

Primary Prevention

Avoidance of alcohol abuse, maintenance of health diet and weight helps in preventing fatty liver.

Secondary Prevention

References

  1. Shelley K, Articolo A, Luthra R, Charlton M (2023). "Clinical characteristics and management of patients with nonalcoholic steatohepatitis in a real-world setting: analysis of the Ipsos NASH therapy monitor database". BMC Gastroenterol. 23 (1): 160. doi:10.1186/s12876-023-02794-4. PMC 10197394 Check |pmc= value (help). PMID 37208593 Check |pmid= value (help).
  2. Reddy JK, Rao MS (2006). "Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation". Am. J. Physiol. Fatty liver disease is one of the most deadly dieases ever to be found in someone who has and its very contasious so if someons has if i were u i wouldnt be hanging around with them well thats all from me see u next time. ËĒȲȳǖGastrointest. Liver Physiol. 290 (5): G852–8. doi:10.1152/ajpgi.00521.2005. PMID 16603729.
  3. 3.0 3.1 Angulo P (2002). "Nonalcoholic fatty liver disease". N. Engl. J. Med. 346 (16): 1221–31. doi:10.1056/NEJMra011775. PMID 11961152.
  4. Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, Omatsu T, Nakajima T, Sarui H, Shimazaki M, Kato T, Okuda J, Ida K (2005). "The metabolic syndrome as a predictor of nonalcoholic fatty liver disease". Ann. Intern. Med. 143 (10): 722–8. PMID 16287793.
  5. Sleisenger, Marvin (2006). Sleisenger and Fordtran's Gastrointestinal and Liver Disease. Philadelphia: W.B. Saunders Company. ISBN 1416002456.
  6. Belfort R, Harrison SA, Brown K; et al. (2006). "A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis". N. Engl. J. Med. 355 (22): 2297–307. doi:10.1056/NEJMoa060326. PMID 17135584.

Template:WS Template:WH